Is Humira a Biosimilar or Brand Name Drug?
Humira (adalimumab) is a brand name biologic drug developed by AbbVie. It is the reference product, not a biosimilar.[1]
What Makes Humira Different from Biosimilars?
Humira is a tumor necrosis factor (TNF) inhibitor approved in 2002 for autoimmune conditions like rheumatoid arthritis and psoriasis. Biosimilars are highly similar versions of reference biologics like Humira, developed by other companies after patents expire. They must prove no clinical differences in safety or efficacy.[1]
Which Biosimilars to Humira Are Approved?
The FDA has approved several Humira biosimilars since 2023, including Amjevita (Amgen), Cyltezo (Boehringer Ingelheim), Hadlima (Samsung Bioepis), and Yusimry (Coherus). Over 10 versions exist, offering lower costs—often 80-85% less than Humira.[2][1]
When Did Humira's Patents Expire?
AbbVie's patents began expiring in January 2023 in the US, with full expiration by 2027 after over 100 patent challenges. This opened the market to biosimilars, though AbbVie extended exclusivity via settlements.[3]
How Do Humira and Biosimilars Compare in Price and Use?
Humira lists at around $6,000+ per month without insurance. Biosimilars start at $1,000-2,000 monthly, driving savings for patients and payers. They are interchangeable with Humira for most indications, but switching requires doctor approval.[2]
Are There Risks Switching from Humira to a Biosimilar?
Clinical trials show biosimilars match Humira's efficacy and safety, with similar injection-site reactions or infections. No unique risks, but patients should monitor for rare immune responses. Medicare covers switches seamlessly.[1]
[1]: FDA Biologics Page on Adalimumab
[2]: DrugPatentWatch.com - Humira Patents and Biosimilars
[3]: USPTO Patent Litigation on Humira